# Athyrium Capital Management LP

> Athyrium Capital Management LP is a VC fund backing Biotechnology. See 47 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 47
- Last investment: Mar 2026
- Lead investor: 60%
- Fund size: $2B
- Last fund: Dec 2017
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/athyrium-capital-management-llc
- Website: http://www.athyrium.com

Athyrium Capital Management LP is a VC fund in New York focused on Biotechnology and Health Care. **Note: CrunchBase does not maintain a complete list of the investments made by the Athyrium funds. Please see our website at www.athyrium.com for a complete list of these investments.**Athyrium Capital Management, LP (“Athyrium”) is a specialized asset management company formed in 2008 to focus on investment opportunities in the globalhealthcare sector.Athyrium is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940.The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities.Athyrium invests across all healthcare verticals including biopharma, medical devices and products, and healthcare services. The team partners with management teams to implement creative financing solutions to companies’ capital needs.Athyrium advises funds with over $1.7 billion of committed capital. We value our investors and are thankful for the trust they have placed in us. Our investors consist of public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds.

## Contacts

5 contacts available for Athyrium Capital Management LP. Shizune tracks 4 team members at Athyrium Capital Management LP. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/athyrium-capital-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 27 | 57% |
| Health Care | 22 | 47% |
| Medical | 17 | 36% |
| Pharmaceutical | 15 | 32% |
| Therapeutics | 5 | 11% |

32 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Debt | 16 | 34% |
| Private Equity | 7 | 15% |
| Debt Financing | 6 | 13% |
| Post-IPO Equity | 5 | 11% |
| Series B | 3 | 6% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 29 | 62% |
| Denmark | 2 | 4% |
| France | 1 | 2% |
| Norway | 1 | 2% |
| Sweden | 1 | 2% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeffrey A Ferrell | Managing Partner | 3 | https://shizune.co/investors/profile/jeffrey-a-ferrell |
| Jeremy D Lack | Partner | 0 | https://shizune.co/investors/profile/jeremy-d-lack |
| Laurent D Hermouet | Partner | 9 | https://shizune.co/investors/profile/laurent-d-hermouet |
| Richard Pines | Partner | 5 | https://shizune.co/investors/profile/richard-t-pines |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Esperion | Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Its prescription medicines focus on lowering elevated low-density lipoprotein cholesterol (LDL-C), a key factor in cardiovascular disease. The company offers oral, non-statin therapies that help reduce cardiovascular risk in patientswho are unable to tolerate or adequately respond to standard statin treatments. Its marketed products include bempedoic acid-based therapies that work by inhibiting ATP citrate lyase (ACLY), an enzyme involved in cholesterol synthesis. These medicines are designed to reduce LDL-C levels and support cardiovascular risk reduction in adults with conditions such as hyperlipidemia and atherosclerotic cardiovascular disease. | $50M | Post-IPO Debt | Mar 03, 2026 |  |
| Orange Twist | Orange Twist provides the ultimate aesthetic experience for their clients, every treatment, every time, everywhere. At OrangeTwist, they believe in getting you to the best possible version of yourself. Whether that means getting rid of some stubborn fat here or a quick touch-up there, they are dedicated to providing the best possible results in themost unique setting. |  | Venture - Series Unknown | Jan 05, 2026 |  |
| Esperion | Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Its prescription medicines focus on lowering elevated low-density lipoprotein cholesterol (LDL-C), a key factor in cardiovascular disease. The company offers oral, non-statin therapies that help reduce cardiovascular risk in patientswho are unable to tolerate or adequately respond to standard statin treatments. Its marketed products include bempedoic acid-based therapies that work by inhibiting ATP citrate lyase (ACLY), an enzyme involved in cholesterol synthesis. These medicines are designed to reduce LDL-C levels and support cardiovascular risk reduction in adults with conditions such as hyperlipidemia and atherosclerotic cardiovascular disease. | $250M | Post-IPO Debt | Dec 13, 2024 |  |
| Vita Health | Vytyl Health Management delivers quality mental health care to adolescents and transitional-age youth. The organization firmly believes that connection forms the basis for healing. They recognize the significant challenges ahead but remain steadfast in their conviction that through collaborative efforts, barriers can be overcome, meaningful bondscan be formed, and vital assistance can be extended to those in greatest need. | $22.5M | Series A | Jan 09, 2024 |  |
| Calliditas Therapeutics | Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States. | $102.2M | Post-IPO Debt | Dec 27, 2023 |  |
| Basilea Pharmaceutica | Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas ofbacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options. | $76.8M | Post-IPO Debt | Sep 07, 2022 |  |
| uMotif | UMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceuticalcompanies to capture rich health data across a range of conditions. | $25.2M | Series B | May 25, 2022 |  |
| Revance Therapeutics | Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as EssentiaBiosystems. | $300M | Post-IPO Debt | Mar 21, 2022 |  |
| Puma Biotechnology | Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to furtherdevelop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer. | $10M | Post-IPO Equity | Mar 10, 2022 |  |
| Osmotica Pharmaceutical | Osmotica Pharmaceutical is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The Company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. | $100M | Post-IPO Debt | Oct 07, 2021 |  |

10 of 47 investments shown.

## Co-investors
- [HealthCare Royalty Partners](https://shizune.co/investors/profile/healthcare-royalty-partners) — VC Fund, 3 deals together
- [First Round Capital](https://shizune.co/investors/profile/first-round-capital) — VC Fund, 2 deals together
- [Hildred Capital Partners](https://shizune.co/investors/profile/hildred-capital-partners) — VC Fund, 2 deals together
- [Pharmascience](https://shizune.co/investors/profile/pharmascience) — VC Fund, 2 deals together
- [Signet Healthcare Partners](https://shizune.co/investors/profile/signet-healthcare-partners) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does Athyrium Capital Management LP invest in?

Athyrium Capital Management LP invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Debt and Private Equity stage. Most of the 47 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Athyrium Capital Management LP?

Public channels for Athyrium Capital Management LP include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Athyrium Capital Management LP?

The team at Athyrium Capital Management LP includes Jeffrey A Ferrell (Managing Partner), Jeremy D Lack (Partner) and Laurent D Hermouet (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co